249 related articles for article (PubMed ID: 14577451)
1. The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements.
Cohen JC; Illingworth P
Dev World Bioeth; 2003 May; 3(1):27-48. PubMed ID: 14577451
[TBL] [Abstract][Full Text] [Related]
2. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
Adekola TA
Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
[TBL] [Abstract][Full Text] [Related]
3. Academic patents and access to medicines in developing countries.
Sampat BN
Am J Public Health; 2009 Jan; 99(1):9-17. PubMed ID: 19008514
[TBL] [Abstract][Full Text] [Related]
4. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
Allard Soto R
Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
[TBL] [Abstract][Full Text] [Related]
5. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
[TBL] [Abstract][Full Text] [Related]
6. Intellectual property rights, the World Trade Organization and public health: the Brazilian perspective.
Viana JM
Conn J Int Law; 2002; 17(2):311-8. PubMed ID: 12688298
[No Abstract] [Full Text] [Related]
7. Balancing access to pharmaceuticals with patent rights.
Nicol D
Monash Bioeth Rev; 2003 Apr; 22(2):50-62. PubMed ID: 15069957
[TBL] [Abstract][Full Text] [Related]
8. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
[TBL] [Abstract][Full Text] [Related]
9. The ethics of intellectual property rights in an era of globalization.
Shah AK; Warsh J; Kesselheim AS
J Law Med Ethics; 2013; 41(4):841-51, Table of Contents. PubMed ID: 24446942
[TBL] [Abstract][Full Text] [Related]
10. Access to life-saving medicines and intellectual property rights: an ethical assessment.
Schroeder D; Singer P
Camb Q Healthc Ethics; 2011 Apr; 20(2):279-89. PubMed ID: 21435303
[No Abstract] [Full Text] [Related]
11. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
12. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues.
Schuklenk U
Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958
[No Abstract] [Full Text] [Related]
13. Intellectual property and pharmaceutical drugs: an ethical analysis.
De George RT
Bus Ethics Q; 2005 Oct; 15(4):549-75. PubMed ID: 16358442
[TBL] [Abstract][Full Text] [Related]
14. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
Cohen-Kohler JC; Forman L; Lipkus N
Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
[TBL] [Abstract][Full Text] [Related]
15. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
Ghosh S
Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
[No Abstract] [Full Text] [Related]
16. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro.
Resnik DB; DeVille KA
Am J Bioeth; 2002; 2(3):29-39. PubMed ID: 12230852
[No Abstract] [Full Text] [Related]
17. Developing drugs for the developing world: an economic, legal, moral, and political dilemma.
Resnik DB
Dev World Bioeth; 2001 May; 1(1):11-32. PubMed ID: 12870505
[TBL] [Abstract][Full Text] [Related]
18. Introduction: Access to life-saving medicines and intellectual property rights.
Schroeder D
Camb Q Healthc Ethics; 2011 Apr; 20(2):277-8. PubMed ID: 21435302
[No Abstract] [Full Text] [Related]
19. Access to medicines and the rhetoric of responsibility.
Barry C; Raworth K
Ethics Int Aff; 2002; 16(2):57-70. PubMed ID: 15709279
[No Abstract] [Full Text] [Related]
20. Trade, TRIPS, and pharmaceuticals.
Smith RD; Correa C; Oh C
Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]